Celgene Corporation (CELG) CEO Discusses Q2 2013 Results - Earnings Call ... Seeking Alpha The results for the CALGB 5803 Phase II study of REVLIMID plus rituximab in patients with previously untreated follicular lymphoma were presented during the International Congress on Malignant Lymphoma. This multi-center study reported a response rate ... |
